Literature DB >> 26120651

[Oligoprogression].

Matthias Guckenberger1.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26120651     DOI： 10.1007/s00066-015-0826-2

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  9 in total

1.  Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer.

Authors:  Puneeth Iyengar; Brian D Kavanagh; Zabi Wardak; Irma Smith; Chul Ahn; David E Gerber; Jonathan Dowell; Randall Hughes; Ramzi Abdulrahman; D Ross Camidge; Laurie E Gaspar; Robert C Doebele; Paul A Bunn; Hak Choy; Robert Timmerman
Journal:  J Clin Oncol       Date:  2014-10-27       Impact factor: 44.544

2.  Erlotinib in previously treated non-small-cell lung cancer.

Authors:  Frances A Shepherd; José Rodrigues Pereira; Tudor Ciuleanu; Eng Huat Tan; Vera Hirsh; Sumitra Thongprasert; Daniel Campos; Savitree Maoleekoonpiroj; Michael Smylie; Renato Martins; Maximiliano van Kooten; Mircea Dediu; Brian Findlay; Dongsheng Tu; Dianne Johnston; Andrea Bezjak; Gary Clark; Pedro Santabárbara; Lesley Seymour
Journal:  N Engl J Med       Date:  2005-07-14       Impact factor: 91.245

3.  Oligometastases.

Authors:  S Hellman; R R Weichselbaum
Journal:  J Clin Oncol       Date:  1995-01       Impact factor: 44.544

4.  Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients.

Authors:  C Collen; N Christian; D Schallier; M Meysman; M Duchateau; G Storme; M De Ridder
Journal:  Ann Oncol       Date:  2014-08-11       Impact factor: 32.976

Review 5.  Oligometastases revisited.

Authors:  Ralph R Weichselbaum; Samuel Hellman
Journal:  Nat Rev Clin Oncol       Date:  2011-03-22       Impact factor: 66.675

6.  Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study.

Authors:  Michael T Milano; Alan W Katz; Hong Zhang; Paul Okunieff
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-12-13       Impact factor: 7.038

7.  Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis.

Authors:  Kyle E Rusthoven; Susan F Hammerman; Brian D Kavanagh; Michael J Birtwhistle; Mark Stares; D Ross Camidge
Journal:  Acta Oncol       Date:  2009       Impact factor: 4.089

8.  Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases.

Authors:  Kyle E Rusthoven; Brian D Kavanagh; Stuart H Burri; Changhu Chen; Higinia Cardenes; Mark A Chidel; Thomas J Pugh; Madeleine Kane; Laurie E Gaspar; Tracey E Schefter
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544

9.  Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer.

Authors:  M Guckenberger; N Andratschke; H Alheit; R Holy; C Moustakis; U Nestle; O Sauer
Journal:  Strahlenther Onkol       Date:  2013-09-21       Impact factor: 3.621
  9 in total
  2 in total

1.  Stereotactic body radiotherapy for lung oligometastases impacts on systemic treatment-free survival: a cohort study.

Authors:  Rosario Mazzola; Sergio Fersino; Giuseppe Ferrera; Giovanni Targher; Vanessa Figlia; Luca Triggiani; Nadia Pasinetti; Antonio Lo Casto; Ruggero Ruggieri; Stefano Maria Magrini; Filippo Alongi
Journal:  Med Oncol       Date:  2018-08-04       Impact factor: 3.064

2.  Improving interinstitutional and intertechnology consistency of pulmonary SBRT by dose prescription to the mean internal target volume dose.

Authors:  L Wilke; C Moustakis; O Blanck; D Albers; C Albrecht; Y Avcu; R Boucenna; K Buchauer; T Etzelstorfer; C Henkenberens; D Jeller; K Jurianz; C Kornhuber; M Kretschmer; S Lotze; K Meier; P Pemler; A Riegler; A Röser; D Schmidhalter; K H Spruijt; G Surber; V Vallet; R Wiehle; J Willner; P Winkler; A Wittig; M Guckenberger; S Tanadini-Lang
Journal:  Strahlenther Onkol       Date:  2021-07-01       Impact factor: 3.621
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.